新生血管性年龄相关性黄斑变性(nAMD)是不可逆视力丧失的主要原因。目前的共识提供了关于诊断的建议,评估,治疗,以及11名执业眼科医生对nAMD的随访策略。专家建议,nAMD管理的基线访问应包括通过视觉和解剖学评估组成的多模式方法进行全面的眼科检查。诊断为nAMD的患者应接受治疗,目的是维持视觉功能,同时减少解剖学疾病活动并最大程度地减少治疗负担。目前,抗VEGF治疗是nAMD的主要治疗策略,建议在完成包括3次每月注射的负荷阶段后1个月内进行全面眼科检查的评估,以指导后续管理.在抗VEGF治疗的维持阶段,可以考虑采用治疗和延长或前纳塔方案。应根据疾病活动选择和调整治疗方案,报销标准,财政负担,和患者偏好。如果nAMD不活跃或治疗效果不佳,经过全面评估和患者教育,可以停止抗VEGF治疗。该共识为眼科医生和其他医疗保健专业人员提供了实用的nAMD管理指南。
Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss. The present
consensus provides suggestions on diagnosis, evaluation, treatment, and follow-up strategies for nAMD from a panel of 11 practicing ophthalmologists. The experts suggest that the baseline visit for nAMD management should include a comprehensive ophthalmologic examination via a multimodal approach consisting of visual and anatomical evaluation. Patients diagnosed with nAMD should be subjected to treatment with the goal of maintaining visual function while diminishing anatomical disease activity and minimizing treatment burden. Currently, anti-VEGF therapy is the main treatment strategy for nAMD, and evaluation involving comprehensive ophthalmologic examination within 1 month of completion of the loading phase comprising three monthly injections is recommended to guide subsequent management. Either a treat-and-extend or pro re nata regimen can be considered for the maintenance phase of anti-VEGF therapy, and the regimen should be chosen and adjusted according to disease activity, reimbursement criteria, financial burden, and patient preferences. In the event of inactive nAMD or poor treatment outcomes, after thorough evaluation and patient education, anti-VEGF therapy may be stopped. The
consensus provides practical nAMD management
guidelines for ophthalmologists and fellow healthcare professionals.